New pill shows promise for tough eczema in small study
NCT ID NCT06585202
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal was to see if the drug is safe and might reduce skin redness, itching, and rash.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATI-2138 oral tablets
What this could lead to
If successful, this could point toward a new oral treatment option for moderate to severe atopic dermatitis, potentially reducing skin inflammation and itching.
What could go wrong
This is a small, early-phase study with only 14 participants and no placebo group, so results may not apply broadly. Side effects are possible, and the drug may not prove effective in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aclaris Investigational Site
Birmingham, Alabama, 35244, United States
-
Aclaris Investigational Site
Encino, California, 91436, United States
-
Aclaris Investigational Site
San Diego, California, 92123, United States
-
Aclaris Investigational Site
Plainfield, Indiana, 46168, United States
-
Aclaris Investigational Site
Austin, Texas, 78759, United States
-
Aclaris Investigational Site
San Antonio, Texas, 78213, United States